VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease. - Test2 - elhamkhani - TriplyDB

VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.

VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.

http://www.wikidata.org/entity/Q34595165

about

Parkinson's disease: animal models and dopaminergic cell vulnerability Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model Spontaneously Hypertensive Rats (SHR) Are Resistant to a Reserpine-Induced Progressive Model of Parkinson's Disease: Differences in Motor Behavior, Tyrosine Hydroxylase and α-Synuclein Expression Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.PET imaging a MPTP-induced mouse model of Parkinson's disease using the fluoropropyl-dihydrotetrabenazine analog [18F]-DTBZ (AV-133)Fungal-derived semiochemical 1-octen-3-ol disrupts dopamine packaging and causes neurodegeneration Vivo-morpholinos induced transient knockdown of physical activity related proteins.Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine.JNK inhibition of VMAT2 contributes to rotenone-induced oxidative stress and dopamine neuron death.Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processing VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discrimination Polymorphism in the Vesicular Monoamine Transporter 2 Gene Decreases the Risk of Parkinson's Disease in Han Chinese Men.Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism.Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease.Olfactory assays for mouse models of neurodegenerative disease.A phenotypic model recapitulating the neuropathology of Parkinson's disease.Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease.Autoimmune Aspects of Neurodegenerative and Psychiatric Diseases: A Template for Innovative Therapy.Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity.Selective genetic disruption of dopaminergic, serotonergic and noradrenergic neurotransmission: insights into motor, emotional and addictive behaviour.Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.Parkinson's disease: experimental models and reality.AGC1-malate aspartate shuttle activity is critical for dopamine handling in the nigrostriatal pathway.Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain.Tyrosine Hydroxylase, Vesicular Monoamine Transporter and Dopamine Transporter mRNA Expression in Nigrostriatal Tissue of Rats with Pedunculopontine Neurotoxic Lesion.Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?

P2860

Q28080503-A4545B86-0CFA-4B4D-997C-CDB0D1FDE0A3 Q28384426-9FFD22E9-D99C-42E2-AE8B-C19BEAF1E276 Q30359033-9A244ECF-BB8A-449D-BE86-A87763606803 Q33724885-C658C938-A132-40DF-83F2-F6FF6B60E9F4 Q34314094-FA8FFF3B-CF97-42EA-B8E2-63288723C5E5 Q34384338-AC0F5103-C6EE-4B40-8D91-4307A43F8A56 Q34695522-59E211F7-5F50-4473-ABB6-647840068021 Q34760266-7B47503C-20CA-4F9B-BFB2-EA8BE51F97E9 Q35019852-B8C7FD2C-9D59-4CEC-8622-C3619938A6E6 Q35031572-9C2910EF-A593-49F6-B43B-3F8D7FD3E216 Q35191319-5E8EFB7B-4529-44CE-9539-515BF69DCAF0 Q35889761-B5E86155-B6C1-4CFB-A94F-D4BBE045D30A Q36590693-C9567DC7-3CBB-4B09-9963-558FE387F143 Q36708352-2FC8F38F-E7BB-4DB6-BC1E-C1C80841502B Q36787949-0981C8A0-CF0F-4FA7-B293-BCCC9B08E7DF Q37407288-514E8C55-5C79-4A4B-A9BA-6ACCE67F7340 Q37701053-DC83E539-04DE-47B5-8086-25C79E8CEBE7 Q37711589-89C967F7-81B8-4F6E-8113-F07EFE25F43A Q37736100-691061CB-3F7B-48FF-B2A3-F06B300A78D5 Q37880260-68C042C3-FB0C-4C0F-BC63-CDB51592E707 Q38926644-33BF27F5-17BE-4CCC-980B-254A0655F0B7 Q39300158-3A01FF58-F69C-4998-BB54-FD8439BEBA45 Q39368224-EBC0BA43-24B9-4031-BCAC-C5E1BE689D4A Q40879980-263D227F-BDD5-43B8-9805-84B08AEB7936 Q41031814-25C6ED48-424E-4342-BA8C-ADEC485B0693 Q42321665-19FE41A5-D802-4A2C-A965-9C895C4D0DA8 Q47389506-FFC46234-216B-4C38-81F4-1408628F28A0 Q47935763-FAF884B4-2DFA-4F45-B754-BDCDD76DB1C9 Q48433008-A47545EC-8872-43D8-8F0B-067C9AC45721 Q49490658-C038C189-7444-4FAC-B7A5-080F35647879 Q52624714-D834CF41-6994-4688-88F4-072CB0F371E1

P2860

VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.

http://www.wikidata.org/entity/Q34595165

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

VMAT2-Deficient Mice Display N ...... mptoms of Parkinson's Disease.

@ast

VMAT2-Deficient Mice Display N ...... mptoms of Parkinson's Disease.

@en

VMAT2-Deficient Mice Display N ...... mptoms of Parkinson's Disease.

@nl

type

label

VMAT2-Deficient Mice Display N ...... mptoms of Parkinson's Disease.

@ast

VMAT2-Deficient Mice Display N ...... mptoms of Parkinson's Disease.

@en

VMAT2-Deficient Mice Display N ...... mptoms of Parkinson's Disease.

@nl

prefLabel

VMAT2-Deficient Mice Display N ...... mptoms of Parkinson's Disease.

@ast

VMAT2-Deficient Mice Display N ...... mptoms of Parkinson's Disease.

@en

VMAT2-Deficient Mice Display N ...... mptoms of Parkinson's Disease.

@nl

P1433

Q34595165-CCDC393D-25AA-4DA5-B629-A9B97F48225E

P1476

Q34595165-A4C53938-09FB-4B53-95D0-4E5808B7DB05

P2093

Q34595165-2145F4C1-0A89-4FFC-A270-5487E1999474

Q34595165-B687967F-AFA9-42AF-9C5F-79B0820AFCEE

Q34595165-C4C3B249-4A9E-437E-BFDE-A5CD0DA8FB0F

P2860

Q34595165-0CF600C7-5D4A-44F5-8D65-F06077559481

Q34595165-16EB0A62-0EBE-4343-9810-3276C261B156

Q34595165-1745CC0E-3BE4-4E09-9CBC-8CD6AA9D2876

Q34595165-1811C368-986C-454A-ACAF-645D2C30C733

Q34595165-1DBC9160-F958-45BD-A76D-C62F7A7026A4

Q34595165-1F344146-BD19-46EB-B5A9-DCF188AAFCD9

Q34595165-1F504482-05A5-4CD9-9C2E-3F291687A219

Q34595165-2102A144-365A-4D4E-8989-E3CA472BF57F

Q34595165-29E8784A-70AA-466D-9C3A-CF67D8549F91

Q34595165-2B131DC9-BEC3-47A9-80C2-F6F98850A073

P304

Q34595165-DEED1CAF-5E64-4F48-A114-FC0384B0D9F3

P31

Q34595165-14CA6554-7481-4FEE-B885-7043C26F9354

P356

Q34595165-101417EB-8125-4599-9588-F6145FBD2172

P478

Q34595165-7742572C-880A-4701-95B3-2C599DB15B97

P577

Q34595165-74301924-F489-4149-8116-E85F083038DB

P5875

Q34595165-47C05303-CB3E-4887-99DA-2616F498074D

P698

Q34595165-D0DC93BB-84CB-4696-B313-2A14AE38D32D

P921

Q34595165-E5FCA56D-407A-4828-B764-9BFF0F1379DD

Q34595165-ded5f863-3f2d-4101-be62-d07494033cdd

P932

Q34595165-5B39E7B9-E2CE-4722-A1E8-84B62D0DCD62

P356

P1433

Parkinson's disease

P1476

VMAT2-Deficient Mice Display N ...... mptoms of Parkinson's Disease.

@en

P2093

Gary W Miller

http://www.w3.org/2001/XMLSchema#string

Tonya N Taylor

http://www.w3.org/2001/XMLSchema#string

W Michael Caudle

http://www.w3.org/2001/XMLSchema#string

P2860

The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine

A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPs

Expression cloning of a reserpine-sensitive vesicular monoamine transporter

Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice

Staging of brain pathology related to sporadic Parkinson's disease

Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration

Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells

The Parkinson's complex: parkinsonism is just the tip of the iceberg

VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity

A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter

P304

124165

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4061/2011/124165

http://www.w3.org/2001/XMLSchema#string

P478

2011

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50396039

http://www.w3.org/2001/XMLSchema#string

P698

21403896

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3043293

http://www.w3.org/2001/XMLSchema#string